Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM

Acute myeloid leukemia (AML) is a disease of the elderly population and survival remains poor after failure of hypomethylating agents (HMA). The BCL‐2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML. In this case series, patients with seco...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Haematol
Main Authors: Huemer, Florian, Melchardt, Thomas, Jansko, Bettina, Wahida, Adam, Jilg, Stefanie, Jost, Philipp J., Klieser, Eckhard, Steiger, Katja, Magnes, Teresa, Pleyer, Lisa, Greil‐Ressler, Sigrun, Rass, Christof, Greil, Richard, Egle, Alexander
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849823/
https://ncbi.nlm.nih.gov/pubmed/30725494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13218
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados